57 results about "Clostridium Infections" patented technology

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.

The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses recombinant epsilon protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant epsilon protein is (a) protein formed by amino acid sequences shown in SEQ ID No.2 or (b) protein formed by amino acid sequences from the 51 site to the 370 site in SEQ ID No.2 or fusion protein obtained by fusing protein tags on carboxyl terminals or / and amino terminals of the (a) protein or the (b) protein. After animals are immune to the recombinant epsilon protein, the animals can generate the high serum antibody level and can resist attack of clostridium perfringens. The recombinant epsilon protein is good in dissolvability and easy to purify and can be taken as a diagnostic antigen or prepared into a monoclonal antibody or used for further studying the protein function and the conformation relationship.

Immunogenic compositions for combating clostridium (C.) difficile infection are disclosed comprising an admixture of at least two components (a) and (b), where component (a) comprises inactivated cells of at least one strain of C. difficile, or or cell surface extracts (CSE) from one or more strains of C. difficile bacteria; and component (b) comprises at least one toxoid or a non-toxic, immunogenic polypeptide fragment of a C. difficile Toxin A or Toxin B. Administration of the immunogenic composition is effective to elicit an immune response in a subject immunized with said composition to produce antibodies reactive with at least one C. difficile strain and at least one C. difficile toxin.

The invention discloses a recombinant lactobacillus for simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin, a construction method of the recombinant lactobacillus and an application. The recombinant lactobacillus takes the clostridium perfringens alpha, beta 1, beta 2 and epsilon exotoxin reconstructed from gene levels in a toxicity removal manner as immunogen, the reconstructed exotoxin completely loses pathogenicity and still retains immunogenicity, and the lactobacillus serves as a safe living bacterium carrier for transmitting and expressing immunizing antigens, so that the recombinant lactobacillus capable of simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin is acquired, and a gene engineering lactobacillus multi-valence subunit toxin oral immune preparation capable of effectively preventing infection of five serotype clostridium perfringens is prevented. The recombinant lactobacillus provides effective technical means for preventing infection of the clostridium perfringens.

The present invention provides the compound represented by formula (I), or its stereoisomer, or its salt, or its solvate, or its prodrug, or its metabolite. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, and has significant antibacterial activity. It has a very good application prospect in the medicine of disease complications.

Methods of treating or preventing a C. difficile infection and the associated pathological conditions related to C. difficile infection, are disclosed.

A method of preventing or treating a subject suffering from Clostiridium difficile infection or its associated symptom includes administering a therapeutic effective amount of a HMGB1 inhibitor to the subject. A method of inhibiting toxin-induced cytotoxic effect in colon cells includes contacting the colon cells with an effective amount of a HMGB1 inhibitor.

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and / or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1 / 027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.